MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts

TH-302 is a hypoxia-activated prodrug known to activate selectively under the hypoxic conditions commonly found in solid tumors. It is currently being evaluated in clinical trials, including two trials in Pancreatic Ductal Adenocarcinomas (PDAC). The current study was undertaken to evaluate imaging...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:PLoS One
Główni autorzy: Zhang, Xiaomeng, Wojtkowiak, Jonathan W., Martinez, Gary V., Cornnell, Heather H., Hart, Charles P., Baker, Amanda F., Gillies, Robert
Format: Artigo
Język:Inglês
Wydane: Public Library of Science 2016
Hasła przedmiotowe:
Research Article
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4882075/
https://ncbi.nlm.nih.gov/pubmed/27227903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0155289
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy